Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence

Status Completed

Clinical Trial Summary

This is an 8 week, outpatient research study testing the use of long-acting naltrexone (Vivitrol) as a treatment for marijuana dependence. Vivitrol is a medication that is effective in treating dependence on opiates and opioids, and in treating dependence on alcohol. It is FDA approved for these disorders. It is a long-acting medication that contains enough medicine in each injection to last for one month. One way it works is by blocking the effects of opiates, including opiates released by the body in response to drugs and alcohol. In this study, we are interested in testing the effects of Vivitrol in people with marijuana dependence.

Individuals participating in this study will receive two Vivitrol injections, each given four weeks apart, (week 1 and week 5). The injection is given in the muscle of the buttock on one side. Participants will attend clinic visits two times a week during this 8-week study for medical management for drug use and for monitoring of physical and psychological health.

Clinical Trial Description

This is an 8 week, outpatient, open-label clinical trial of long-acting injectable naltrexone as a treatment for cannabis dependence.

The purpose of the study will be to evaluate marijuana use patterns and tolerability of long-acting naltrexone in 7 treatment-seeking, cannabis-dependent outpatients; also to assess feasibility of conducting a larger trial with this medication. Cannabis dependent patients will have twice weekly clinic visits where they will receive injections of Vivitrol four weeks apart, in Week 1 and in Week 5. The psychosocial intervention for this study will be Medical Management, designed to facilitate adherence to the study medication and monitoring procedures, as well as to support the participant in achieving his or her marijuana use goals.

Participants will self-report cannabis use, will provide urine toxicology for quantitative assessment of THC (Tetrahydrocannabinol, the active ingredient in marijuana), and will provide serum samples for safety monitoring, and will answer questionnaires and will report on their physical and psychological health weekly. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02088177
Study type	Interventional
Source	New York State Psychiatric Institute
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	October 2014
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01005810` - A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana	Phase 2
Completed	`NCT00114439` - Lithium Cannabis Withdrawal Study	Phase 2
Completed	`NCT00350285` - The Teen Marijuana Check-Up	Phase 2
Completed	`NCT01618656` - Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal	Phase 2
Completed	`NCT01153490` - Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine	Phase 4
Completed	`NCT02946489` - Facilitating the Behavioral Treatment of Cannabis Use Disorder	Phase 1
Not yet recruiting	`NCT01565174` - The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis	N/A
Completed	`NCT01697709` - Quetiapine Pharmacotherapy for Cannabis Dependence	Phase 2
Recruiting	`NCT04721353` - Reducing Cannabis Overuse With Prazosin	Phase 4
Completed	`NCT01603992` - Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
Completed	`NCT00167297` - Atomoxetine for the Treatment of Cannabis Dependence	Phase 2
Terminated	`NCT01598896` - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia	Phase 2/Phase 3
Completed	`NCT01611948` - Treatment for Cannabis Withdrawal and Dependence	Phase 2
Recruiting	`NCT03221231` - N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms	Phase 4
Not yet recruiting	`NCT03366909` - Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness	N/A
Completed	`NCT01639872` - Clozapine for Cannabis Use in Schizophrenia	Phase 4
Not yet recruiting	`NCT06334016` - Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream	Early Phase 1
Completed	`NCT01793961` - Effects of Chronic Intake of Cannabis on Contrast Sensitivity	N/A
Completed	`NCT01747850` - Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence	Phase 2
Completed	`NCT01834794` - Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.